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PERSPECTIVE
Parallel phase 1 clinical trials in the US 
and in China: accelerating the test of avitinib 
in lung cancer as a novel inhibitor selectively 




Avitinib, a new generation inhibitor of epidermal growth factor receptor (EGFR), was approved for clinical trial in both 
China and the United States, and the phase 1 trials were initiated in both countries in parallel. In the preclinical stud-
ies, avitinib showed three novel features including (1) irreversibly binding EGFR by forming a covalent bound with Cys 
797 in the ATP-binding pocket, (2) sparing wild-type EGFR, and (3) overcoming T790M-induced resistance. Avitinib is 
the first China-developed novel EGFR inhibitor that has entered in global clinical trials, and will provide a precision 
targeted therapy for non-small cell lung cancer patients.
© 2015 Xu. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://
creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided 
you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate 
if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/
zero/1.0/) applies to the data made available in this article, unless otherwise stated.
The patients with non-small cell lung cancer (NSCL) 
containing somatic mutations of the epidermal growth 
factor receptor (EGFR) gene, such as the small deletions 
(747–750) and point mutations at codon 858 (L858R), are 
highly responsive to the currently marketed EGRF inhibi-
tors [1–4]. These mutations on the EGFR gene mediate 
oncogenic effects by altering downstream signaling and 
antiapoptotic mechanisms, and such oncogenic effects 
can be inhibited by currently marketed EGFR inhibi-
tors (e.g. gefitinib, erlotinib, and icotinib), which are 
together termed as the first-generation EGFR inhibitors. 
Despite the dramatic responses to such inhibitors, most 
patients ultimately have a relapse, and more than 50% 
of them developed a second point mutation resulting in 
threonine-to-methionine amino acid change at the posi-
tion 790 of EGFR (T790M) [5], which is also termed as 
a gatekeeper mutation. The T790M mutation leads to 
the resistance against first-generation EGFR inhibitors. 
A newer irreversible EGFR inhibitor afatinib, so-called 
the second-generation EGFR inhibitor, has been recently 
approved by the Food and Drug Administration (FDA) 
in the United States (US). Although the inhibition of 
the T790M EGFR can be detected in the animal models 
and have been studied most frequently in the setting of 
acquired resistance to the first-generation EGFR inhibi-
tors, the results from clinical studies did not clearly sup-
port that the treatment-resistant patients benefited from 
the second-generation EGFR inhibitor as a single drug 
treatment. In addition, because of the strong inhibition 
of wild-type EGFR, the second-generation EGFR inhibi-
tor appears to have more adverse effects than first-gen-
eration EGFR inhibitors. Thus far, no standard therapeu-
tic methods are available for the patients who relapsed 
after the treatment of first-generation EGFR inhibitors. 
New therapeutic intervention is urgently needed for the 
relapse.
In December 2009, a new generation EGFR inhibitor 
concept was reported by a group in Dana-Farber Cancer 
Institute [6]. The reported study aimed to explore a novel 
therapeutic method to overcome the T790M gatekeeper 
mutation-induced resistance after the treatment of first-
generation EGFR inhibitors. In the study, an experimental 
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compound, WZ4002, reported as a third-generation 
EGFR inhibitor, showed three novel features: (1) irre-
versibly binding EGFR by forming a covalent bound with 
Cys 797 in the ATP-binding pocket, (2) sparing wild-type 
EGFR, and (3) overcoming T790M-induced resistance. 
Shortly after the concept was published, we launched a 
program of developing a third-generation EGFR inhibitor 
as a novel therapeutic agent for overcoming the T790 M 
resistance, and the program was designed for both China 
and US FDA submission and global clinical trials at the 
very beginning. Therefore, in addition to meeting the 
high quality standard of science in the early discovery 
and development phase, fully understanding the regula-
tory guidance in China and US FDA and integrating the 
requirements from both regulatory agencies to the early 
development plan and strategy became the key to ensure 
the success of the preclinical studies and innovative new 
drug (IND) submission. Although both regulatory agen-
cies require a very comprehensive preclinical IND data 
packages for innovative drugs, there are some differ-
ences. For the China FDA submission, the standards of 
Chemistry, Manufacturing, Control (CMC) package are 
almost close to the level of a final drug product, and the 
mechanisms of action and drug efficacy should be fully 
validated, whereas, for US FDA submission, the safety 
package including the full analysis of off-target effects of 
the compound and the clinical protocol should be well 
prepared to ensure the safety and ethic of the testing 
drug in human trials. In the preclinical studies, avitinib 
as an irreversible EGFR inhibitor showed the unique fea-
tures of the third-generation EGFR inhibitor reported 
by the Dana-Farber group with strong potent inhibitory 
activities against EGFR bearing both active mutations 
and T790M mutations, and a better selectivity between 
wild-type EGFR and mutant EGFR. Avitinib has a great 
safety profile in rats and monkeys and can be orally 
administrated with good bioavailability and pharmacoki-
netic properties. The IND for avitinib was submitted to 
Center for Drug Evaluation (CDE), China FDA in August 
2013 and approved for clinical trials in China in Septem-
ber 2014; in the US, the IND for avitinib was submitted 
to FDA in August 2014, and the clinical trial was granted 
in September 2014. The approval allowed avitinib clinical 
trials to be initiated in China and the US in parallel.
The clinical trials of avitinib were started in China and 
the US as the second-line therapy for NSCLC patients 
who have developed the resistance to first-generation 
EGFR inhibitors and acquired the gatekeeper muta-
tion, T790M. In China, the clinical studies were started 
in Sun Yat-sen University Cancer Center, Guangdong 
People’s General Hospital, and Beijing Union Hospital 
(clinical pharmacology studies) for the dose escalation 
assessments on drug safety, pharmacokinetics, and effi-
cacy. NSCLC patients with EGFR active mutations and 
having developed the resistance against first-generation 
EGFR inhibitors will be enrolled in the trials, and the 
T790M status will be further confirmed by genetic tests 
in biopsy tissue samples and blood samples. The multi-
center trial will soon be initiated in China to expand the 
patient population at selected doses to further explore 
the safety and efficacy. In the US, the clinical studies 
were initiated in MD Anderson Cancer Center and other 
three university hospitals. The US phase I trial protocol is 
similar to the China trial protocol, and China clinical trial 
data are used as a reference for the US trials, such as the 
starting dose, the dose escalation design, dose schedules 
(once or twice a day), and possible adverse event control 
and monitoring schedules. To keep the consistence of the 
trial data, especially the experimental data, trials in both 
China and the US will use the same protocols, testing 
kits, and central labs. Thanks to the significant improve-
ment in China clinical trials and participation in global 
clinical trials during last decade led by Chinese principal 
investigators and multinational pharmaceutic compa-
nies, we will be able to design the avitinib China trials as 
a part of the global trials soon being initiated in the US 
and other regions of the world. Therefore, avitinib devel-
opment strategy will be able to be designed as an innova-
tive drug not only for China but as an innovative global 
drug development program starting from China. At the 
time of this article’s submission, the clinical trials have 
followed the proposed trial timeline and patients have 
begun to benefit from the treatment of avitinib.
Conducting clinical trials in China and the US for an 
innovative drug developed in China is challenging and 
costly, whereas such trials have been considered an 
absolutely necessary step towards globalization of the 
China-innovated drugs. The successful IND approval and 
initiation of clinical trials for avitinib in both China and 
the US may offer a breakthrough therapeutic opportunity 
to address the urgent needs for NSCLC patients not only 
in China but also outside China. In addition, the ongoing 
global clinical development of avitinib will further enrich 
our knowledge and experiences of how to improve the 
global development process of domestically developed 
anticancer drugs.
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